These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 3810552)

  • 1. The fibrinolytic system in experimental prostate tumor.
    Al-Mondhiry H; Drago J; Bartholomew MJ
    Thromb Haemost; 1986 Oct; 56(2):133-6. PubMed ID: 3810552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients.
    Wada H; Mori Y; Okabayashi K; Gabazza EC; Kushiya F; Watanabe M; Nishikawa M; Shiku H; Nobori T
    Am J Hematol; 2003 Jan; 72(1):1-7. PubMed ID: 12508260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
    Collatos C; Barton MH; Prasse KW; Moore JN
    J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer].
    Pflüger H; Kirchheimer J; Ritschl P; Köller A; Hienert G; Binder BR
    Wien Klin Wochenschr; 1984 Sep; 96(17):658-61. PubMed ID: 6083673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of coagulation and fibrinolytic system in prostate cancer.
    Kohli M; Kaushal V; Mehta P
    Semin Thromb Hemost; 2003 Jun; 29(3):301-8. PubMed ID: 12888934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor metastasis and the fibrinolytic system].
    Yamamura M; Yamamoto M
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1246-54. PubMed ID: 2730023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disseminated intravascular coagulation syndrome (D.I.C.) and carcinoma of the prostate (author's transl)].
    Becopoulos T; Kranides A; Mandalaki-Yianitsiotis T; Louizou K; Panagiotopoulou E; Dimopoulos C
    J Urol (Paris); 1980; 86(6):467-70. PubMed ID: 6160184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the fibrinolytic system in calves implanted with an artificial heart and ventricular assist device.
    al-Mondhiry H; Pae WE; Pierce WS
    ASAIO J; 1995; 41(1):95-9. PubMed ID: 7727829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury.
    Idell S
    Crit Care Med; 2003 Apr; 31(4 Suppl):S213-20. PubMed ID: 12682443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
    Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
    Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
    Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
    Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Behavior of plasminogen in prostatic carcinoma treated with cytonal].
    Oehler D; Kätzel R; Brunner HP
    Z Urol Nephrol; 1980 Dec; 73(12):923-9. PubMed ID: 6452764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alterations of fibrinolysis in stroke].
    Hernández Nuñez A; Romero Barbero JL; Cáceres Sansaloni A; Pérez de Oteyza C
    An Med Interna; 1996 Mar; 13(3):107-10. PubMed ID: 8679836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.